Coeptis Therapeutics

Coeptis Therapeutics, formerly known as Vinings Holdings, Inc., was renamed to Coeptis Therapeutics on July 12, 2021. Coeptis Therapeutics is a pharmaceutical company focused on the development of innovative therapies and technologies that have the potential to disrupt traditional treatment paradigms and improve patient outcomes. Coeptis's portfolio includes two clinical-stage candidates (CPT1550 and CPT60621) and two approved drugs, Conjupri™ and conseni®. Coeptis’s pipeline has evolved from current partnerships established with multiple pharmaceutical companies. As these relationships develop, the product pipeline will be updated accordingly.